Catalyst Pharmaceuticals (CPRX) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.99% |
| Dec 31, 2025 | 27.90% |
| Sep 30, 2025 | 23.15% |
| Jun 30, 2025 | 39.97% |
| Mar 31, 2025 | 52.78% |
| Dec 31, 2024 | 41.93% |
| Sep 30, 2024 | 34.88% |
| Jun 30, 2024 | 35.46% |
| Mar 31, 2024 | 42.88% |
| Dec 31, 2023 | 53.81% |
| Sep 30, 2023 | 53.27% |
| Jun 30, 2023 | 53.21% |
| Mar 31, 2023 | 31.77% |
| Dec 31, 2022 | 64.22% |
| Sep 30, 2022 | 77.64% |
| Jun 30, 2022 | 59.06% |
| Mar 31, 2022 | 33.15% |
| Dec 31, 2021 | 44.64% |
| Sep 30, 2021 | 53.78% |
| Jun 30, 2021 | 41.18% |
| Mar 31, 2021 | 20.01% |
| Dec 31, 2020 | 37.02% |
| Sep 30, 2020 | 32.84% |
| Jun 30, 2020 | 38.65% |
| Mar 31, 2020 | 31.26% |
| Dec 31, 2019 | 38.40% |
| Sep 30, 2019 | 45.68% |
| Jun 30, 2019 | 46.25% |
| Mar 31, 2019 | -26.85% |
| Dec 31, 2018 | -15.28% |
| Sep 30, 2018 | -32.88% |
| Jun 30, 2018 | -21.37% |
| Mar 31, 2018 | -21.91% |
| Dec 31, 2017 | -19.71% |
| Sep 30, 2017 | -19.05% |
| Jun 30, 2017 | -22.80% |
| Mar 31, 2017 | -24.32% |
| Dec 31, 2016 | -25.14% |
| Sep 30, 2016 | -21.22% |
| Jun 30, 2016 | -24.31% |
| Mar 31, 2016 | -48.14% |
| Dec 31, 2015 | -43.20% |
| Sep 30, 2015 | -45.65% |